Theresa Medina

Hematology | Oncology

1665 Aurora Ct
Fl 2
Aurora, CO 80045

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma.

Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma.

Journal: JAMA dermatology

Published: July 08, 2026

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 01, 2026

CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II Trial.

CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II Trial.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 29, 2026

CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II Trial.

CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II Trial.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Decitabine reverses innate immune gene suppression in rare melanomas.

Decitabine reverses innate immune gene suppression in rare melanomas.

Journal: Molecular cancer therapeutics

Published: November 04, 2025

Decitabine reverses innate immune gene suppression in rare melanomas.

Decitabine reverses innate immune gene suppression in rare melanomas.

Journal: bioRxiv : the preprint server for biology

Published: September 05, 2025

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.

Journal: Journal for immunotherapy of cancer

Published: July 04, 2025

Autologous Thymic Organoids Support Functional T-cell Education and Enhance Antitumor Immunity in Humanized Mice with Melanoma Xenografts.

Autologous Thymic Organoids Support Functional T-cell Education and Enhance Antitumor Immunity in Humanized Mice with Melanoma Xenografts.

Journal: Cancer research communications

Published: June 28, 2025

The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study.

The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 27, 2025

Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study.

Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 02, 2025

Real world experience with omission of therapeutic lymph node dissection in clinical stage III malignant melanoma treated with checkpoint or kinase inhibition systemic therapy.

Real world experience with omission of therapeutic lymph node dissection in clinical stage III malignant melanoma treated with checkpoint or kinase inhibition systemic therapy.

Journal: Surgical oncology insight

Published: April 10, 2025

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.

Journal: Cancer

Published: April 08, 2025

Showing 1-12 of 49

Last Updated: 09/26/2026